Biocryst
Navenibart
STAR-0215 / Hereditary angioedema / Phase 3 / Hereditary angioedema prophylaxis
Pipeline Watchlist
Company Pipelines
Recent additions
14 daysbiocryst.com
Bioatla
BA3362
Oncology
Bioatla
BA3241
Oncology / Preclinical / Solid tumors
Bioatla
BA3311
Oncology / Preclinical / Solid tumors
Bioatla
BA3142
Oncology / Preclinical / Solid tumors
Bioatla
BA3151
Oncology / Preclinical / Breast cancer
Axsome
AXS-20
CNS / Phase 3-enabling / Schizophrenia
Autolus
AUTO4
Oncology / Phase 1 / PTCL
Autolus
obe-cel
obecabtagene autoleucel / Oncology; Autoimmune disease / Phase 1 / B-NHL
Aura Biosciences
belzupacap sarotalocan
AU-011 / oncology / Phase 3 / early choroidal melanoma (small choroidal melanoma and/or indeterminate lesions)
Ataibeckley
Novel 5-HT2A Receptor Agonists
Mental health / In development / Opioid Use Disorder
Ascendis Pharma
TransCon CNP + TransCon hGH
navapegritide + lonapegsomatropin / Endocrinology rare diseases / Phase 2 / Achondroplasia (children aged 2-11)
Companies
AXSMAxsome
6assets
Axsome
- AXS-05AXS-05 / AUVELITY / NMDA receptor; sigma-1 receptor; CYP2D6 / oral small molecule / CNSSmoking cessationPhase 2/3 plannedon track to initiate in 2Q 2026US
- SolriamfetolSUNOSI / dopamine and norepinephrine reuptake; TAAR1; 5-HT1A / oral small molecule / CNSPediatric ADHDPhase 3 plannedtwo trials on track to initiate in 2Q 2026USMDD with excessive daytime sleepiness symptomsPhase 3CLARITY initiated February 2026USBinge eating disorderPhase 3ENGAGE ongoingUS
- AXS-12AXS-12 / norepinephrine reuptake inhibitor; cortical dopamine modulator / oral small molecule / CNSCataplexy in narcolepsyNDA submittedFDA filing acceptance decision pendingUS
- AXS-14AXS-14 / norepinephrine reuptake inhibitor / oral small molecule / CNSFibromyalgiaPhase 3FORWARD ongoingUS
- AXS-17AXS-17 / GABAA receptor alpha2,3 positive allosteric modulator / oral small molecule / CNSEpilepsyPhase 2-enablingtrial-enabling activities underwayUS
- AXS-20AXS-20 / PDE10A / oral small molecule / CNSSchizophreniaPhase 3-enablingtrial-enabling activities anticipated in 2026USTourette syndromeplanned evaluationUS